Image courtesy of Insilico Medicine

A biotech company that’s received over $400 million from investors for its artificial intelligence-based research opens a new headquarters in Cambridge this week in a relocation from New York City.

Insilico Medicine is basing its senior leadership of 15 executives in finance, business development and marketing at 1000 Massachusetts Ave. after signing a 3,000 square foot lease, a spokesperson said.

Founded by CEO Alex Zhavoronkov, the 10-year-old company has raised over $400 million from various investors including B Capital Group, Warburg Pincus, BHR Partners, Deerfield and BOLD Capital. In 2022, Sanofi signed a $1.2 billion deal with Insilico to accelerate its drug development pipeline using the firm’s AI technology.

Insilico Medicine will retain space at its previous headquarters at the CURE Innovation campus in Manhattan, but plans to “grow organically” in Cambridge, the spokesperson said.

The 108,982-square-foot retail-office building at 1000 Massachusetts Ave. is owned by Intercontinental Real Estate Corp., which acquired it in 2016 for $69.5 million.

AI Biotech Researchers Relocate to Cambridge

by Steve Adams time to read: 1 min